Wag! Group Co.

    Wag! Group Co.

    NNASDAQ:PET
    0.05
    USD
    0.00
    (0.00%)
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    0.32
    0.53
    2.94
    2.19
    1.58
    1.22
    Basic EPS, GAAP
    -0.5
    -0.17
    -2.07
    -0.35
    -0.39
    -0.44
    Free Cash Flow per Basic Share
    -0.7
    -0.32
    -0.15
    -0.18
    -0.2
    -0.16
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -2.73
    -2.9
    -7.96
    -4.21
    -4.01
    -3.82
    Tangible Book Value per Share
    -2.64
    -2.91
    0.32
    -0.31
    -0.27
    -0.37
    Basic Weighted Avg Shares
    38
    38
    19
    38
    45
    50
    Sales/Revenue/Turnover
    12
    20
    55
    84
    71
    61
    Operating Margin (%)
    -158.49
    -52.41
    -56.73
    -8.63
    -14.73
    -27
    Depreciation Expense
    - -
    - -
    1
    2
    2
    3
    Net Income, GAAP
    -19
    -6
    -39
    -13
    -18
    -22
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -157.39
    -31.43
    -70.29
    -15.87
    -24.92
    -36.53
    Working Capital
    14
    2
    31
    13
    -14
    -21
    LT Debt
    5
    1
    25
    26
    - -
    - -
    Total Equity
    -100
    -106
    10
    2
    - -
    -8
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'24
    Mar'25
    Jun'25
    ST Debt
    19
    19
    20
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    50
    51
    51
    Market Capitalization
    11
    7
    12

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'24
    Mar'25
    Jun'25
    Total Current Assets
    15
    15
    11
    Cash, Cash Equivalents & STI
    6
    6
    3
    Accounts Receivable, Net
    7
    6
    6
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    29
    32
    32
    Payables & Accruals
    9
    10
    8
    ST Debt
    19
    19
    20
    Deferred Revenue
    1
    3
    5

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    -129.71%
    Free Cash Flow
    - -
    - -
    29.43%
    Net Income, GAAP
    - -
    - -
    31.92%
    Sales/Revenue/Turnover
    - -
    - -
    -15.98%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    21
    20
    22
    22
    84
    2024
    23
    19
    13
    15
    71
    2025
    15
    17
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.1
    -0.1
    -0.06
    -0.09
    -0.35
    2024
    -0.11
    -0.06
    -0.13
    -0.1
    -0.39
    2025
    -0.1
    -0.12
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • defenseworld.net

      Pet Valu Holdings Ltd. (TSE:PET) Stock Has Consensus Target Price of C$25.00

    • defenseworld.net

      Pet Valu (TSE:PET) Stock Price Crosses Above 200-Day Moving Average – Should You Sell?

    • seekingalpha.com

      Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More

    • gurufocus.com

      GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68

    • defenseworld.net

      Pet Valu Holdings Ltd. (TSE:PET) Stock Rated “Moderate Buy” by Sell-Side Brokerages

    • globenewswire.com

      Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

    • zacks.com

      BASF Expands Ultradur Portfolio With Recycled PET Grades

    • zacks.com

      GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal

    • wsj.com

      GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical imaging procedures like PET scans

    • proactiveinvestors.com

      Grey Matters Health taps ProScan for brain PET scan interpretation in Florida

    • proactiveinvestors.com

      Grey Matters Health to open first NovaScan Neuroimaging Clinic in September

    • globenewswire.com

      Grey Matters Announces September Opening of its First Brain Dedicated PET Neuroimaging Clinic in the U.S.

    • gurufocus.com

      Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease

    • proactiveinvestors.com

      Grey Matters Health expands brain imaging services – ICYMI

    • proactiveinvestors.com

      Grey Matters Health takes delivery of first brain-dedicated PET scanner for Florida clinic

    • globenewswire.com

      Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida

    • newsfilecorp.com

      Pet Valu Holdings Ltd. (PET) Closes the Market

    • newsfilecorp.com

      Yellowbird Diagnostics Completes Dosing in First-in-Human Phase 1 Trial of NeuCaVis(TM)

    • gurufocus.com

      GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations

    • globenewswire.com

      AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS